Why Amgen Is Buying Onyx for $10.4B

Aug. 26 (Bloomberg) -- Amgen agreed to buy Onyx Pharmaceuticals in a $10.4 billion transaction that gives Amgen access to a rapidly expanding cancer-drug market with a new product that offers sure revenue. Olivia Sterns reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

Most Recent Videos

How Apple Conquered China Market: Bloomberg West (01/30)
35:26 - Jan. 30 -- Full episode of "Bloomberg West." Guests: GGV Capital's Hans Tung, Strategic Analytics' Neil Mawston, Evercore ISI's Ken Sena, CKE Restaurants CEO Andrew Puzder, Boost VC CEO Adam Draper and Zebra Technologies' Jill Stelfox.
  • Should Amazon Spin Off Its Growing Cloud Business?
  • TripAdvisor's Top Pick: Chicago's Langham Hotel
  • Dan Marino: Roger Goodell Has Done a Really Good Job